Take Solutions Limited · NSE:TAKE
Take Solutions — Investor Presentation (March 2019)
44 slides from Take Solutions's investor presentation, March 2019
Slide 1: TAKE Solutions Limited
TAKE Solutions Limited The Only Listed Full-service CRO In India March 2019
Slide 2: At A Glance
At A Glance Europe HQ: Frankfurt, 20 offices across 20,390 Germany Major trial operations USA HQ: Princeton, NJ center in Germany and sites through Europe Revenue FY19 12 countries Clinical, Regulatory & Safety Specialists in UK, (INR Mn) consulting and technology centers. Sweden, Germany, Clinical
Slide 3: TAKE is a preferred partner for Life Sciences Companies
TAKE is a preferred partner for Life Sciences Companies , Improving Efficiency And Driving Better Outcomes Across The Drug Development Value Chain Copyright TAKE Solutions Limited 2019
Slide 4: Life Sciences Drug Development Landscape
Life Sciences Drug Development Landscape Bringing a drug to the market is a complex process involving many time consuming and expensive stages US $1 – 1.5 Billion per Drug! Drug Discovery Pre-clinical Trials Clinical Trials (Phase I to III) Regulatory Approval Post-approval ~ 5 Years ~ 1 Year ~ 7 Ye
Slide 5: Where Do We Come In?
Where Do We Come In? US $1 – 1.5 Billion per Drug! Drug Discovery Pre-clinical Trials Clinical Trials (Phase I to III) Regulatory Approval Post-approval ~ 5 Years ~ 1 Year ~ 7 Years ~ 1.5 Years On Going Basic Research (R&D) Molecule formulation (compound) is identified to combat a disease Clinical T
Slide 6: Life Sciences
As a strategic partner, TAKE Solutions delivers full-service Clinical, Regulatory and Safety services and solutions to the Life Sciences Industry LIFE SCIENCES Copyright TAKE Solutions Limited 2019
Slide 7: Need for Outsourcing in Life Sciences
Need for Outsourcing in Life Sciences A paradigm shift is taking place in Life Sciences R&D R&D Marketing & Clinical Marketing & Clinical Branding Research Branding Research Sponsor Sponsor Company Company Regulatory Regulatory Manufacturing Manufacturing Affairs Outsourced Affairs Safety (PV) Inhou
Slide 8: Life Sciences Outsourcing
Life Sciences Outsourcing An Attractive Growth Opportunity The USD 36.8 Bn Life Sciences Outsourcing Industry is expected to reach USD 43.9 Bn by 2021 Clinical 84% Life Sciences Life Sciences Life Sciences Life Sciences Outsourcing Outsourcing Outsourcing Outsourcing USD 36.8 Bn USD 38.8 Bn USD 41.1
Slide 9: Life Sciences Outsourcing: Proportion of Cost Outsourced
Life Sciences Outsourcing What Proportion of Development Cost is being Outsourced? Outsourcing trend is Picking Up Across All Segments, And there is still Significant Headroom left for growth 2017 2021 Large Innovator 39% 45% SME Innovator 50% 57% Generics 43% 52% Government 26% 30% Others 19% 21% I
Slide 10: Types of Sponsors
Types of Sponsors Who is Outsourcing? Although Large Innovators account for the majority, Mid / Small Innovators are an equally attractive segment in this space! Generics accounts for 10% The Mid/Small Innovators Large Innovators (Turnover >US$ 5Bn) (Turnover US$ 1-5 Bn) account are responsible for
Slide 11: Why Do Sponsors Choose Us?
Why Do Sponsors Choose Us? Our Unique Formula = Technology Platform Based Services + Knowledge Partner Clinical Regulatory Capabilities Services across Full Operational Capabilities Markets Nets Industry Forums Technology Consulting Experts Across The Globe Innovative Platforms Safety Offering both
Slide 12: We Deliver Results
We Deliver Results 120+ Network Members The only company to host 7,500+ 150,000+ 10 unique proprietary 400+ Sites Regulatory Clinical Trials Submissions Life Sciences industry network forums! 1,000+ BABE Studies 120,000+ 300+ Multiple Accreditations/certifications 1,500+ Patients & Volunteers Safety
Slide 13: Our Life Sciences Journey
Our Life Sciences Journey We have built our Clinical, Regulatory and Safety offerings organically… Regulatory Regulatory Clinical Regulatory Capabiliti Capabiliti Capabiliti es across Services es across Services Services es across Markets Markets Nets Markets Nets Consulting Consulting Technology Sa
Slide 14: Our Global Life Sciences Brand
Our Global Life Sciences Brand Over the years, we have built/acquired Now, we unified them all to form our many life sciences brands… Global Go-to-Market Brand Uniform Product A Unified Global Brand Has Consistent Improved Brand Offerings & Delivery Messaging Three Key Advantages Awareness / Recall
Slide 15: Our People Strength Across the Globe
Our People Strength Across the Globe AMERICAS EUROPE We are dependent on highly skilled manpower and with a global FY 19 470 employees FY 19 134 employees presence. The availability of the right resources has not been a challenge FY 18 345 employees FY 18 195 employees 26% 27% Engineering and LS & T
Slide 16: High-quality global trials enabled by our proprietary eClinical platform
100+ Innovator and Generics Sponsors We deliver High-quality, global trials 400+ Clinal Trials enabled by our proprietary eClinical platform 1,000+ BA/BE Studies Conducted Clinical Trials for the Conducted USPTO Patent for “Method for 1st Stem Cell Product in the 8% of All Biosimilars Trials in Opti
Slide 17: Key Clinical Offerings
Key Clinical Offerings CDM, Biostatistics & Programing, Data Investigator Standardization, Payment MW Full-service Biosimilars Clinical Trials (P1-4) Non- OneClinical intervention Our Optimized eClinical and Analytics al Studies BA/ BE Clinical Trials Management Platform Offers Comprehensive Trial O
Slide 18: How Do We Help Our Clients?
How Do We Help Our Clients? Case Study: Full-service phase II stem cell therapy study Business Need Results Sponsor required a full- service phase II stem cell 1st stem cell-based study in a rare patient pool product approved by DCGI with high screen fail rate “ We Greatly Appreciate the valued cont
Slide 19: We help life sciences companies Stay Compliant
Submissions Across 130+ Countries 35,000+ Paper Submissions 95,000+ We help life sciences eCTD companies Stay Compliant 150,000+ Global Regulatory 20,000+ Submissions* NeeS 5+ USA, APAC & Unique Technology Submitted Propositions LATAM 6% of Total Regulatory Regulatory Hubs Submissions to USFDA 2012-
Slide 20: Key Regulatory Offerings
Key Regulatory Offerings with over 175 clients, End To End is a fully integrated web-based eDMS and Labelling eCTD Submissions And Artwork traceREADY is a next generation mobility Submissions Management platform & Report Services Publishing labelREADY is a end-to-end label management platform rimREA
Slide 21: How Do We Help Our Clients?
How Do We Help Our Clients? Case Study: Global publishing and submission management for top 5 pharma Results Business Need • Successful delivery of 30% of • Make 45k submissions annually the Client’s global requirement across multiple health • ~30% efficiency gain over authorities baseline • Maintai
Slide 22: Minimize Risks across the product lifecycle
We help life sciences companies Minimize Risks across the product lifecycle 30+ 100+ Years in PV* Member Companies of our PV Networks We have successfully completed 300+ Safety Consulting Engagements *through acquisition of WCI Consulting Copyright TAKE Solutions Limited 2019 www.takesolutions.com
Slide 23: Key Safety Offerings
Key Safety Offerings Adverse Event Reporting Safety Risk Management Signal Management Benefit Risk Governance End-to-End PV Services Services safetyREADY™ An accelerated solution for implementation, upgrade and migration for Oracle’s Argus Safety suite E2E PV Optimization Safety Medical Governance T
Slide 24: How Do We Help Our Clients?
How Do We Help Our Clients? Case Study: Making a mid-size biotech compliant with latest EU regulation changes Results Business Need • The baseline benefit-risk profile of 200+ products was Upcoming regulatory changes established and is actively necessitated an overhaul of the monitored Safety system
Slide 25: Proud Partners across all Segments
Clientele Proud Partners across all Segments! Copyright TAKE Solutions Limited 2019 25 www.takesolutions.com
Slide 26: TAKE's Board comprises of Directors Who Are Experts In Their Fields
Governance Practices TAKE’s Board comprises of 12 Directors Who Are Experts In Their Fields 6 Independent Directors Including an Independent Chairman 4 Executive Directors 2 Non-Executive Audit We have gender inclusive Committee board consisting of 3 A relatively Young Board Women Directors Risk Sta
Slide 27: Leadership & Experts
Leadership & Experts Srinivasan H R D V Ravi Vice Chairman & MD Director Srinivasan HR, Founder of TAKE Solutions. He D.V. Ravi, Co-founder of TAKE Solutions. He is also the brings over 3 decades of leadership and has Managing Director of Shriram Capital, a financial services held significant leader
Slide 28: Group Structure
Group Structure 3 Entities 2 Entities 5 Entities 4 Entities in India in Singapore in US in UK One holding company and two One holding company and All acquired through M&A All acquired through M&A other operational entities. one operational company and need to be retained and need to be retained Whil
Slide 29: Copyright TAKE Solutions Limited 2019
Copyright TAKE Solutions Limited 2019 29
Slide 30: Our Supply Chain Management Solutions
Our Supply Chain Management Solutions Engineering Sourcing Design & build high Smart global quality products sourcing programs with continuous without the engagement and associated risks extended support and hassles Engineering Services Technology Compliance PIM, e-commerce, Compliance enterprise so
Slide 31: Copyright TAKE Solutions Limited 2019
Copyright TAKE Solutions Limited 2019
Slide 32: Vision 2021: USD $500 Million Life Sciences R&D Specialist
To be a USD $500 Million Vision 2021 Life Sciences R&D Specialist We are on track to achieve our 5 Year Vision $500 Mn $400 Mn $292 Mn $246 Mn $200 Mn 2017 2018 2019 2020 2021 www.takesolutions.com Copyright TAKE Solutions Limited 2019
Slide 33: Delivering Growth with Healthy Margins
Delivering Growth with Healthy Margins 22.27% Adjusted EBITDA Margins 21.34% 20.88% 20.27% Adjusted 19.63% Operating EBITDA 20.46% 20.70% 20.46% Margins 19.50% 19.31% 20,390 15,872 FY19 Reported Operating EBITDA INR 3,834.61 Mn (18.81%) 13,446 FY19 Reported EBITDA 10,301 INR 3,942.10 Mn (19.23%) Ope
Slide 34: TAKE Solutions' Growth Journey
TAKE Solutions’ Steadily shifted focus to Life Sciences to Drive Growth Growth Journey Technology Company Technology-Enabled Services Organization Platform-driven CRO 23% CAGR 10% CAGR 19% CAGR 23% 10% CAGR 11% CAGR CAGR FY 2008 FY 2009 FY 2010 FY 2011 FY 2012 FY 2013 FY 2014 FY 2015 FY 2016 FY 2017
Slide 35: Significantly Ramped Up Our Global Clinical Trials Capabilities
Significantly Ramped Up Our Global Clinical Trials Capabilities FY16 FY17 FY18 FY19 Clinical Regulatory& Safety/PV Consulting & Nets Legend: Limited offerings + Limited Limited offerings + Extended Extended offerings + Extended Full-service offerings Geographical Presence Geographical Presence Geogr
Slide 36: Region Wise Breakup
Region Wise Breakup Europe FY19 FY18 FY17 4.1% 6.5% 7.4% APAC FY19 FY18 FY17 Americas 12.3% 13.4% 13.3% FY19 FY18 FY17 83.6% 80.1% 79.3% % - Revenue Contribution Copyright TAKE Solutions Limited 2019 36 www.takesolutions.com
Slide 37: Capitalizing On The Potential For Life Sciences
Capitalizing On The Potential For Life Sciences 12% 8% 18% 23% 29% Life Sciences Revenue Has Grown by 88% 92% 38% (CAGR) 77% 82% over 5 years! 71% 92% Revenue from Life Sciences FY15 FY16 FY17 FY18 FY19 (FY19) Life Sciences Supply Chain Management Copyright TAKE Solutions Limited 2019 37 www.takesol
Slide 38: Snapshot of Year-on-Year Returns
Snapshot of Year-on-Year Returns 17.2% 17.4% ROCE 13.6% 14.6% (Return on Capital Employed) 13.3% 19.9% 18.0% RoNW (Return on 14.5% 14.0% Net worth) 12.5% FY15 FY16 FY17* FY18** FY19 * - QIP dilution in FY17 ** - Preferential share allotment in FY18 Copyright TAKE Solutions Limited 2019 38 www.takeso
Slide 39: Peer Comparison
Peer Comparison A Large A Large CRO A Large CRO A Large CRO A Large CRO Biologics (Balance (Balance (Balance (Balance Co. Sheet Size Sheet Size Sheet Size Sheet Size (Balance $532 Mn) $968 Mn) $2354 Mn) $7255 Mn) Sheet Size $22549 Mn) 30% 20% 20% 17% 19% EBITDA Margins 13% 1.1 1.2 0.7 0.5 0.6 Asset
Slide 40: A Change in Trajectory
A Change in Trajectory The acquisition of WCI Consulting changed the focus of our Business Pre-Acquisition Post-Acquisition Launching in 2019 Our thought leadership forums, We Rapidly grew the membership base of existing forums, and developed by WCI is Our Key Launched 6 New Forums. We are on track
Slide 41: A Successful Acquisition
A Successful Acquisition The acquisition of Ecron Acunova fast-tracked our growth in the Clinical Outsourcing Space 29% 35% 27% % of Revenue % of Revenue from Clinical % of Revenue from from Clinical Business Clinical Business Business FY17 FY18 FY19 Copyright TAKE Solutions Limited 2019 41 www.take
Slide 42: TAKE uses platform-based services to provide 360 Degree Coverage
TAKE uses platform-based services to provide 360 Degree Coverage of the life sciences domain, Increasing Speed To Market and Reducing Cost of drug development www.takesolutions.com Copyright TAKE Solutions Limited 2019
Slide 43: Disclaimer
Disclaimer This presentation contains certain “forward-looking statements” concerning our future operations, prospects, strategies, financial condition, future economic performance (including growth and earnings), demand for our products and services and other statements of our plan, beliefs, expect
Slide 44: Thank You
THANK YOU www.takesolutions.com